A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment
Status:
Completed
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the
effect of mild, moderate, and severe hepatic impairment due to liver cirrhosis on the
pharmacokinetics of ACT-541468.